Supplementary Table 1 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

Autor: Mark J. Ratain, Thomas F. Gajewski, Gini F. Fleming, Samir D. Undevia, Jacqueline Ramirez, Larry House, Kristin Moshier, Kammi Fox-Kay, Michael L. Maitland, Anitha Nallari, Yuanyuan Zha, Kimberly Napoli Eaton, Masha Kocherginsky, Christine Hartford, Kehua Wu, Ezra E.W. Cohen

PDF file - 63K, Dosing Summary of Sirolimus Phase I Studies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206292380f9ab70e68615770c510f06d
https://doi.org/10.1158/1078-0432.22451424

Data from Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

Autor: Mark J. Ratain, William J. Elliott, Walter M. Stadler, Samir D. Undevia, Henry R. Black, Laura Sit, Kristin Moshier, Theodore Karrison, Kristen E. Kasza, Michael L. Maitland

Purpose: Hypertension is a mechanism-based toxicity of sorafenib and other cancer therapeutics that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. This prospective, single-center, cohort study characterized ambulatory blood

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::736b6ea5cf4df745a3923fd6e4af5c05
https://doi.org/10.1158/1078-0432.c.6517455

Supplementary Table 2 from Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

Autor: Mark J. Ratain, Thomas F. Gajewski, Gini F. Fleming, Samir D. Undevia, Jacqueline Ramirez, Larry House, Kristin Moshier, Kammi Fox-Kay, Michael L. Maitland, Anitha Nallari, Yuanyuan Zha, Kimberly Napoli Eaton, Masha Kocherginsky, Christine Hartford, Kehua Wu, Ezra E.W. Cohen

PDF file - 36K, Patient Characteristics

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a3e48037e9a231ef05a8517ab08b7b
https://doi.org/10.1158/1078-0432.22451418.v1

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Autor: Peter J. O'Dwyer, Mark J. Ratain, Robert G. Maki, Stan B. Kaye, Charles M. Rudin, Gary K. Schwartz, David Khayat, Ahmad Awada, Joanna Vitfell-Rasmussen, Jennifer Obel, Maja DeJonge, Rebecca Kristeleit, Philippe L. Bedard, David R. D'Adamo, Ian B. Walters, Mark A. Dickson, Judith de Vos-Geelen, Samir D. Undevia, Jacek Jassem, Albiruni Ryan Abdul Razak, David Geary, Jacques Medioni, Jacques DeGreve, T.R. Jeffry Evans, Robin L. Jones, Michael B. Sawyer, Bruce Brockstein, Lillian L. Siu, Linda Janisch, Jean-François Baurain

Publikováno v: European journal of cancer (Oxford, England : 1990), Vol. 120, p. 132-139 (2019)
European journal of cancer, 120
European Journal of Cancer, 120, 132-139. Elsevier Ltd.
European Journal of Cancer, 120, 132-139. ELSEVIER SCI LTD

Background: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ova

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43175dba0c26a55ee4ed2d4c6e2f81f8
https://hdl.handle.net/2078.1/237856

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model

Autor: Walter M. Stadler, Gino Metko, Rashmi Chugh, Kent A. Griffith, Bruce Brockstein, J. D. Zavala, Elizabeth J. Davis, Dafydd G. Thomas, Scott M. Schuetze, Samir D. Undevia

Publikováno v: Annals of Oncology

BACKGROUND Insulin-like growth factor receptor (IGF-1R) has been studied as an oncologic target in soft tissue sarcoma (STS), but its role in sarcoma biology is unclear. Anti-IGF-1R antibody cixutumumab demonstrated acceptable toxicity but limited ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07efc5d1ecb8b1abd86eeaacc6ddfd24
https://doi.org/10.1093/annonc/mdv171